Mark Coleman bought $200k of AXSM
director at Axsome Therapeutics, Inc.. 1,575 shares at an average of $127.28, traded Sep 8, 2025, filed Sep 9, 2025.
Score components
- +15RoleDirector
- +12Trade size$200k at market
- 0Relative to holdingsHoldings up 3.4%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-113874, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2025 | POpen-market purchase Common Stock | +800 | $127.20 | $102k | 47,437 | Sep 9, 2025 |
| Sep 8, 2025 | POpen-market purchase Common Stock | +287 | $127.30 | $37k | 47,724 | Sep 9, 2025 |
| Sep 8, 2025 | POpen-market purchase Common Stock | +488 | $127.40 | $62k | 48,212 | Sep 9, 2025 |
Related signals
Other insiders at Axsome Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $2.1M 10,000 shares | -100% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $1.2M 10,000 shares | -100% | |
| 45Moderate | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $5.2M 45,783 shares | -792% | |
| 50Moderate | Axsome Therapeutics, Inc. | Herriot Tabuteau Chief Executive Officer | $7.4M 62,880 shares | -179% | |
| 30Weak | Axsome Therapeutics, Inc. | Mark E Saad director | $1.1M 9,127 shares | -48% | |
| 40Moderate | Axsome Therapeutics, Inc. | Roger Jeffs director | $1.7M 13,464 shares | -19% | |
| 38Weak | Axsome Therapeutics, Inc. | Roger Jeffs director | $7.3M 60,000 shares | -46% | |
| 33Weak | Axsome Therapeutics, Inc. | Roger Jeffs director | $4.4M 36,694 shares | -22% | |
| 33Weak | Axsome Therapeutics, Inc. | Hunter R. Murdock General Counsel | $1.4M 13,514 shares | -180% | |
| 33Weak | Axsome Therapeutics, Inc. | Hunter R. Murdock General Counsel | $2.3M 22,500 shares | -300% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.